As more anti-EGFR resistance related and candidate therapeutically targeted genetic alterations are identified, comprehensive molecular diagnostic approaches are needed to match CRC patients with the appropriate therapies [13]. This evidence concerns the gene EGFR and colorectal carcinoma.